Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed its provisional Q3 2024 consolidated revenue of KRW 1.1871T (+14.81% YoY) and operating profit of KRW 338.6B (+6.29% YoY). Cumulative revenue for the first three quarters reached KRW 3.2909T, with cumulative operating profit at KRW 994.4B.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Provisional Operating Results Based on Consolidated Financial Statements (Fair Disclosure)
- Period Covered: Q3 2024 (Jul 1, 2024 – Sep 30, 2024) and Q3 Cumulative
- Q3 2024 Consolidated Provisional Results (Unit: KRW million, %):
- Revenue:
- Current Period (Q3 ’24): KRW 1,187,075 million (+2.61% QoQ, +14.81% YoY)
- Cumulative: KRW 3,290,883 million (+25.55% YoY Cumulative)
- Operating Profit:
- Current Period (Q3 ’24): KRW 338,578 million (-22.08% QoQ, +6.29% YoY)
- Cumulative: KRW 994,388 million (+30.20% YoY Cumulative)
- Profit Before Income Tax:
- Current Period (Q3 ’24): KRW 290,999 million (-37.41% QoQ, -8.00% YoY)
- Cumulative: KRW 996,036 million (+30.32% YoY Cumulative)
- Net Profit (Same for Controlling Interest):
- Current Period (Q3 ’24): KRW 264,468 million (-16.83% QoQ, +10.03% YoY)
- Cumulative: KRW 761,822 million (+34.36% YoY Cumulative)
- Revenue:
- Information Provision Details:
- Provider: IR Team
- Target Audience: Domestic and foreign investors, media, etc.
- Date & Time: October 23, 2024
- Other Important Details:
- Related IR materials will be posted on the company website (http://www.samsungbiologics.com).
- Figures are provisional prior to completion of external audit and are subject to change.
- Related Disclosure: October 10, 2024: Advance Notice of Financial Results Announcement
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Provisional Results and Verification with Final Quarterly Report
This disclosure provides notice of Samsung Biologics’ provisional operating performance for Q3 2024.
Checking the finalized figures following completion of the external audit and detailed financial statements in the upcoming Q3 quarterly report is essential.
Relevant details can be verified in the subsequent Q3 2024 quarterly report and official filings.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
